JD HEALTH (06618.HK) -3.200 (-6.617%) Short selling $160.42M; Ratio 21.399% reported 1Q revenue growth of 17% YoY, in line with the broker's expectations, Nomura said in a research report. Non-IFRS operating profit grew 48% YoY to RMB1.9 billion, on the ride of gross margin expansion due to enhanced supply chain capabilities and faster growth in high-margin advertising revenue. However, owing to fair value losses arising from certain wealth management products, non-operating income declined YoY. During the period, non-IFRS net profit increased only 6% YoY to RMB1.9 billion.Related NewsJD HEALTH (06618.HK) Falls Over 5% as Nomura Cuts TP to HKD67, Maintains BuyNomura believed JD HEALTH's current share price is equivalent to 12x 2026E adjusted P/E, which it considered attractive. The broker maintained a Buy rating but lowered its TP from HKD80 to HKD67, based on 21x 2026E adjusted P/E. (HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-15 16:25.)
AASTOCKS Financial News